[1] WHO. World malaria report 2024. Geneva: World Health Organization; 2024. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024.
[2] Feng XY, Zhang L, Tu H, Xia ZG. Malaria elimination in China and sustainability concerns in the post-elimination stage. China CDC Wkly 2022;4(44):990 − 4. https://doi.org/10.46234/ccdcw2022.201.
[3] Feng XY, Feng J, Zhang L, Tu H, Xia ZG. Vector control in China, from malaria endemic to elimination and challenges ahead. Infect Dis Poverty 2022;11(1):54. https://doi.org/10.1186/s40249-022-00971-3.
[4] Yin JH, Li M, Yan H, Zhou SS, Xia ZG. Laboratory diagnosis for malaria in the elimination phase in China: efforts and challenges. Front Med 2022;16(1):10 − 6. https://doi.org/10.1007/s11684-021-0889-7.
[5] WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. https://www.who.int/publications/i/item/9789241597531.
[6] World Health Organization. Global malaria programme: WHO guidelines for malaria. 2024. https://www.who.int/publications/i/item//guidelines-for-malaria.
[7] Zhang L, Feng J, Zhang SS, Xia ZG, Zhou SS. The progress of national malaria elimination and epidemiological characteristics of malaria in China in 2017. Chin J Parasitol Parasit Dis 2018;36(3):201-9. https://d.wanfangdata.com.cn/periodical/ChtQZXJpb2RpY2FsQ0hJMjAyNTA2MTcxNjU3NTMSFnpnanNjeHlqc2NienoyMDE4MDMwMDEaCHhyYjhmaTM2. (In Chinese).
[8] Huang F, Liu H, Yan H, Zhou SS, Xia ZG. Antimalarial drug resistance surveillance in China, 2016-2020. China CDC Wkly 2021;3(17):366 − 71. https://doi.org/10.46234/ccdcw2021.099.
[9] WHO. Malaria surveillance, monitoring & evaluation: a reference manual. Geneva: World Health Organization; 2018. https://www.who.int/publications/i/item/9789241565578.
[10] WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018. https://iris.who.int/handle/10665/274362.
[11] Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505(7481):50 − 5. https://doi.org/10.1038/nature12876.
[12] Mulenga MC, Sitali L, Ciubotariu II, Hawela MB, Hamainza B, Chipeta J, et al. Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia. Malar J 2021;20(1):329. https://doi.org/10.1186/s12936-021-03859-z.
[13] de Abreu-Fernandes R, Almeida-de-Oliveira NK, Gama BE, Gomes LR, De Lavigne Mello AR, de Queiroz LT, et al. Plasmodium falciparum Chloroquine-pfcrt resistant haplotypes in Brazilian endemic areas four decades after CQ withdrawn. Pathogens 2023;12(5):731. https://doi.org/10.3390/pathogens12050731.